JEDDAH (RAHNUMA): The third phase of a COVID-19 vaccine clinical trial is to be carried out on at least 5,000 volunteers in Saudi Arabia after clearing mid-stage tests.
In an effort to expedite vaccines against coronavirus, the Ministry of Health announced its preparedness to launch the third phase in health centers across Riyadh, Makkah and Dammam. The clinical trials come as part of a ministry agreement with the Chinese vaccine developing company CanSino.
The findings of the first randomized controlled trial, published in The Lancet, resulted in the vaccine appearing to be safe and inducing a significant immune response in the majority of recipients in the second phase.
The vaccine uses a harmless cold virus, known as adenovirus type-5 (Ad5), to carry genetic material from coronavirus into the body.The volunteers will be over the age of 18.
Ministry spokesman Dr. Mohammed Al-Abd Al-Aly told a press conference on Sunday that epidemiological analysis had shown a fluctuation in confirmed coronavirus cases, with a slight increase potentially caused by social gatherings during Eid Al-Adha that did not adhere to health protocols.
“These numbers are currently at a slight increase, but they are not a cause of major concern (at the moment) for outbreaks or clusters,” the spokesman said.
Estimates of COVID-19 patients needing critical care have decreased in the past three days and the current curve shows a 5.5 percent decrease in admissions. There are currently 1,816 patients in Saudi Arabia receiving critical care.
The Kingdom recorded 1,428 new cases on Sunday, raising the total number of infections to 288,690 since the beginning of the pandemic.
There were 1,599 new recoveries, raising the total number of recoveries to 252,039. There are currently 33,484 active cases.
Saudi Arabia recorded 37 new fatalities on Sunday, raising the coronavirus death toll to 3,167.
There have been 58,424 polymerase chain reaction tests carried out in the past 24 hours, raising the total number of tests in the Kingdom to over 3.8 million.